Evidence map›Paper›PMID 37162506›Full record

ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2023

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn's Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study.

Panu Wetwittayakhlang, Christine Verdon, Michael Starr, Gustavo Drügg Hahn, Petra A Golovics, Talat Bessissow, Waqqas Afif, Gary Wild, Alain Bitton, Peter L Lakatos

Open access · diamondAbstract read
In one paragraph

Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Review
  3. Gasdermin D: A New Inflammatory Biomarker in Assessing Clinical Disease Activity in Crohn's Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Panu WetwittayakhlangDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada;Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Christine VerdonDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
Michael StarrDivision of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.
Gustavo Drügg HahnDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada; Universidade Federal do Rio Grande do Sul, School of Medicine, Graduate Course Sciences in Gastroenterology and Hepatology, Porto Alegre, Brazil.
Petra A GolovicsDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada; Department of Gastroenterology, Hungarian Defence Forces, Medical Centre, Budapest, Hungary.
Talat BessissowDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
Waqqas AfifDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
Gary WildDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
Alain BittonDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
Peter L LakatosDivision of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada; Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
McGill University Health Centre · CAPrince of Songkla University · THSemmelweis University · HUUniversidade Federal do Rio Grande do Sul · BRZrínyi Miklós National Defence University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndoscopic healing is a key treatment target in inflammatory bowel disease; few data are available on the clinical and endoscopic efficacy of biological therapy in upper gastrointestinal Crohn's disease. This study aimed to investigate small bowel mucosal healing and clinical efficacy of adalimumab therapy by video capsule endoscopy in patients with endoscopically active upper gastrointestinal Crohn's disease.

methodsThis prospective, open-label, single-arm study included Crohn's disease patients with moderate-severe endoscopic proximal small bowel involvement, defined by a Lewis score >790. Patients were treated with adalimumab monotherapy for 24 weeks. Co-primary outcomes were endoscopic healing, defined as Lewis score <350, and endoscopic response, defined as >50% decrease in Lewis score. Secondary outcomes included clinical (Harvey-Bradshaw index <4) and biomarker remission (fecal calprotectin <250 μg/g, and C-reactive protein <5 mg/L).

resultsA total of 59 Crohn's disease patients were screened; 17 patients have met eligibility criteria and were enrolled. Endoscopic healing was observed in 8 patients (47.1%) and endoscopic response in additional 5 patients (29.4%) at 24 weeks. Median Lewis score was significantly decreased compared to baseline (1912 vs. 337, P = .0005). Eleven of 13 patients (84.6%) with clinical activity achieved clinical remission (baseline: 13/17 vs. week 24: 2/17, P < .0001). Nine of 10 patients with elevated C-reactive protein achieved normal C-reactive protein after treatment and the median C-reactive protein significantly decreased from 7.4 to 1.6 mg/L, P = .032. In contrast, no change was observed in fecal calprotectin pre- and posttreatment.

conclusionsAdalimumab induced endoscopic healing and clinical remission in patients with active small bowel Crohn's disease, with approximately half of the patients achieving endoscopic healing.

Indexed as

Crohn DiseaseAdalimumabC-Reactive ProteinHumansLeukocyte L1 Antigen ComplexProspective StudiesRemission InductionTreatment OutcomeAdalimumabC-Reactive ProteinLeukocyte L1 Antigen Complex

Identifiers

PMID37162506
PMCPMC10441132
OpenAlexW4376113684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.